PL2553118T3 - Sposób przewidywania nawrotu raka sutka podczas leczenia endokrynologicznego - Google Patents
Sposób przewidywania nawrotu raka sutka podczas leczenia endokrynologicznegoInfo
- Publication number
- PL2553118T3 PL2553118T3 PL11710526T PL11710526T PL2553118T3 PL 2553118 T3 PL2553118 T3 PL 2553118T3 PL 11710526 T PL11710526 T PL 11710526T PL 11710526 T PL11710526 T PL 11710526T PL 2553118 T3 PL2553118 T3 PL 2553118T3
- Authority
- PL
- Poland
- Prior art keywords
- breast cancer
- cancer recurrence
- endocrine treatment
- prediction under
- recurrence prediction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10158561 | 2010-03-31 | ||
| EP11710526.2A EP2553118B1 (en) | 2010-03-31 | 2011-03-29 | Method for breast cancer recurrence prediction under endocrine treatment |
| PCT/EP2011/054855 WO2011120984A1 (en) | 2010-03-31 | 2011-03-29 | Method for breast cancer recurrence prediction under endocrine treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2553118T3 true PL2553118T3 (pl) | 2015-03-31 |
Family
ID=43857901
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11710526T PL2553118T3 (pl) | 2010-03-31 | 2011-03-29 | Sposób przewidywania nawrotu raka sutka podczas leczenia endokrynologicznego |
| PL14188791T PL2845911T3 (pl) | 2010-03-31 | 2011-03-29 | Sposób przewidywania nawrotu raka sutka podczas leczenia endokrynologicznego |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14188791T PL2845911T3 (pl) | 2010-03-31 | 2011-03-29 | Sposób przewidywania nawrotu raka sutka podczas leczenia endokrynologicznego |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US20130065786A1 (pl) |
| EP (2) | EP2845911B1 (pl) |
| JP (2) | JP5940517B2 (pl) |
| KR (1) | KR101864855B1 (pl) |
| CN (2) | CN105821125A (pl) |
| BR (2) | BR112012024718A2 (pl) |
| CA (1) | CA2793133C (pl) |
| ES (2) | ES2525382T3 (pl) |
| HU (1) | HUE030164T2 (pl) |
| MX (1) | MX2012011167A (pl) |
| PL (2) | PL2553118T3 (pl) |
| PT (2) | PT2553118E (pl) |
| RU (1) | RU2654587C2 (pl) |
| UA (1) | UA110790C2 (pl) |
| WO (1) | WO2011120984A1 (pl) |
| ZA (1) | ZA201207229B (pl) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030198972A1 (en) | 2001-12-21 | 2003-10-23 | Erlander Mark G. | Grading of breast cancer |
| PL2553118T3 (pl) | 2010-03-31 | 2015-03-31 | Sividon Diagnostics Gmbh | Sposób przewidywania nawrotu raka sutka podczas leczenia endokrynologicznego |
| PL2737081T3 (pl) | 2011-07-28 | 2017-04-28 | Sividon Diagnostics Gmbh | Sposób przewidywania odpowiedzi na chemioterapię u pacjenta cierpiącego na lub u którego występuje ryzyko wystąpienia nawrotu raka sutka |
| WO2013070521A1 (en) * | 2011-11-08 | 2013-05-16 | Genomic Health, Inc. | Method of predicting breast cancer prognosis |
| WO2013177245A2 (en) * | 2012-05-22 | 2013-11-28 | Nanostring Technologies, Inc. | Nano46 genes and methods to predict breast cancer outcome |
| WO2013188600A1 (en) * | 2012-06-12 | 2013-12-19 | Washington University | Copy number aberration driven endocrine response gene signature |
| WO2013190081A1 (en) * | 2012-06-22 | 2013-12-27 | Proyecto De Biomedicina Cima, S.L. | Methods and reagents for the prognosis of cancer |
| EP2951317B1 (en) | 2013-02-01 | 2017-10-11 | Sividon Diagnostics GmbH | Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer |
| JP2014236726A (ja) * | 2013-05-07 | 2014-12-18 | 独立行政法人国立がん研究センター | 胃がんの再発を予測する方法 |
| CA2912445A1 (en) * | 2013-05-13 | 2014-11-20 | Nanostring Technologies, Inc. | Methods to predict risk of recurrence in node-positive early breast cancer |
| CA2920062A1 (en) * | 2013-08-02 | 2015-02-05 | Universite Catholique De Louvain | Signature of cycling hypoxia and use thereof for the prognosis of cancer |
| EP3044335B1 (en) * | 2013-09-11 | 2020-09-09 | Bio Theranostics, Inc. | Predicting breast cancer recurrence |
| AU2014321200A1 (en) * | 2013-09-23 | 2016-05-05 | The University Of Chicago | Methods and compositions relating to cancer therapy with DNA damaging agents |
| KR101548830B1 (ko) * | 2013-12-30 | 2015-08-31 | 가천대학교 산학협력단 | 줄기세포 배양방법을 이용하여 발굴된 유방암 줄기세포 마커를 이용한 유방암 예후 예측용 조성물 |
| RU2711452C2 (ru) * | 2014-01-22 | 2020-01-17 | Конинклейке Филипс Н.В. | Усовершенствованная стратификация пациентов для оценки пригодности терапии |
| RU2566732C1 (ru) * | 2014-07-08 | 2015-10-27 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт онкологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИ онкологии" СО РАМН) | Способ прогнозирования лимфогенного метастазирования при инвазивной карциноме неспецифического типа молочной железы |
| CN104263815B (zh) * | 2014-08-25 | 2017-01-25 | 复旦大学附属肿瘤医院 | 一组用于激素受体阳性乳腺癌预后的基因及其应用 |
| WO2016092299A1 (en) * | 2014-12-09 | 2016-06-16 | Medical Research Council | Methods and kits for predicting the response to therapy of cancer |
| EP3274476B1 (en) | 2015-03-25 | 2023-06-07 | The General Hospital Corporation | Digital analysis of circulating tumor cells in blood samples |
| CA3016677A1 (en) * | 2016-03-09 | 2017-09-14 | Myriad International Gmbh | Method for determining the risk of recurrence of an estrogen receptor-positive and her2-negative primary mammary carcinoma under an endocrine therapy |
| JP6938536B2 (ja) * | 2016-04-14 | 2021-09-22 | アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ | 新規のｖｅｇｆｒ２コレセプターであるｓｃｕｂｅ２の阻害による、腫瘍血管新生の抑制 |
| JP7131773B2 (ja) * | 2016-04-29 | 2022-09-06 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ホルモン受容体に関連する転写活性の標的尺度 |
| CN106480201A (zh) * | 2016-10-26 | 2017-03-08 | 北京鑫诺美迪基因检测技术有限公司 | 乳腺癌转移评估试剂盒 |
| CN110050075B (zh) * | 2016-10-27 | 2024-04-02 | 通用医疗公司 | 用于确定特定癌症的癌症疗法的功效的血液样品的数字分析 |
| KR101950717B1 (ko) * | 2016-11-23 | 2019-02-21 | 주식회사 젠큐릭스 | 유방암 환자의 화학치료 유용성 예측 방법 |
| KR101896545B1 (ko) * | 2016-11-25 | 2018-09-07 | 주식회사 젠큐릭스 | 유방암 환자의 예후 예측 방법 |
| RU2671557C1 (ru) * | 2017-07-10 | 2018-11-02 | Александр Григорьевич Тоневицкий | Набор реагентов для определения риска возникновения рецидива онкологических заболеваний молочной железы |
| EP3679160A4 (en) * | 2017-09-08 | 2021-05-19 | Myriad Genetics, Inc. | METHOD OF USING BIOMARKERS AND CLINICAL VARIABLES TO PREDICT THE BENEFIT OF CHEMOTHERAPY. |
| EP3743534B1 (en) * | 2018-01-22 | 2022-03-23 | Liquid Biopsy Research LLC | Methods for colon cancer detection and treatment monitoring |
| CN108441559B (zh) * | 2018-02-27 | 2021-01-05 | 海门善准生物科技有限公司 | 一种免疫相关基因群作为标志物在制备评估高增殖性乳腺癌远处转移风险的产品中的应用 |
| JP7199045B2 (ja) * | 2018-04-13 | 2023-01-05 | 国立大学法人大阪大学 | 乳癌の予後に関する情報の取得方法、乳癌の予後の判定装置及びコンピュータプログラム |
| CN108715804A (zh) * | 2018-05-14 | 2018-10-30 | 浙江大学 | 一种群智能寻优的肺癌癌细胞检测仪 |
| CN108424969B (zh) * | 2018-06-06 | 2022-07-15 | 深圳市颐康生物科技有限公司 | 一种生物标志物、诊断或预估死亡风险的方法 |
| JP2020028278A (ja) * | 2018-08-24 | 2020-02-27 | 国立大学法人九州大学 | 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法 |
| WO2020118245A1 (en) * | 2018-12-06 | 2020-06-11 | Georgia State University Research Foundation, Inc. | Quantitative centrosomal amplification score to predict local recurrence of ductal carcinoma in situ |
| WO2021004934A1 (en) * | 2019-07-05 | 2021-01-14 | Intellexon Gmbh | Determining individual hla patterns, use as prognosticators, target genes and therapeutic agents |
| WO2021055517A1 (en) * | 2019-09-16 | 2021-03-25 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treatments based upon molecular characterization of breast cancer |
| KR102325945B1 (ko) * | 2020-04-22 | 2021-11-12 | 아주대학교산학협력단 | 두경부암 예후 예측용 바이오마커 조성물 |
| EP3907301A1 (en) * | 2020-05-08 | 2021-11-10 | Istituto Europeo di Oncologia S.r.l. | Methods and kits for determining the risk of breast cancer recurrence |
| CN112852968A (zh) * | 2021-04-08 | 2021-05-28 | 杨文琳 | 基于免疫相关lncRNA构建三阴性乳腺癌风险预测方法 |
| CN114480652A (zh) * | 2022-02-21 | 2022-05-13 | 深圳市陆为生物技术有限公司 | 评价乳腺癌患者对于辅助内分泌治疗的响应性的产品 |
| CN115998886A (zh) * | 2022-08-22 | 2023-04-25 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | Trim29在乳腺癌免疫治疗中应用 |
| WO2026008886A1 (en) * | 2024-07-05 | 2026-01-08 | Immatics Biotechnologies Gmbh | Means and methods for the quantification of target expression |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| JP4277452B2 (ja) | 2000-02-25 | 2009-06-10 | ソニー株式会社 | 記録装置、再生装置 |
| EA006512B1 (ru) * | 2001-04-27 | 2005-12-29 | Институт молекулярной биологии им. В.А.Энгельгардта РАН | Способы анализа последовательностей нуклеиновых кислот с использованием биологического олигонуклеотидного микрочипа и наборы для их осуществления |
| AU2002346008A1 (en) | 2001-06-28 | 2003-03-03 | Dermtech International | Method for detection of melanoma |
| US20040002067A1 (en) | 2001-12-21 | 2004-01-01 | Erlander Mark G. | Breast cancer progression signatures |
| US20060024692A1 (en) * | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| FR2863275B1 (fr) * | 2003-12-09 | 2007-08-10 | Biomerieux Sa | Procede pour le diagnostic/pronostic du cancer du sein |
| EP1721159B1 (en) * | 2004-02-20 | 2014-12-10 | Janssen Diagnostics, LLC | Breast cancer prognostics |
| BRPI0515562A (pt) * | 2004-09-22 | 2008-07-29 | Tripath Imaging Inc | métodos e composições para avaliação do prognóstico do cáncer de mama |
| WO2006052731A2 (en) | 2004-11-05 | 2006-05-18 | Genomic Health, Inc. | Molecular indicators of breast cancer prognosis and prediction of treatment response |
| JP2008536094A (ja) | 2005-02-04 | 2008-09-04 | ロゼッタ インファーマティクス エルエルシー | 乳癌患者における化学療法反応性を予測する方法 |
| CA2608643A1 (en) * | 2005-05-13 | 2006-11-16 | Universite Libre De Bruxelles | Gene-based algorithmic cancer prognosis |
| WO2006138275A2 (en) | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US20070099209A1 (en) * | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| GB0512299D0 (en) | 2005-06-16 | 2005-07-27 | Bayer Healthcare Ag | Diagnosis prognosis and prediction of recurrence of breast cancer |
| WO2007030611A2 (en) * | 2005-09-09 | 2007-03-15 | The Board Of Regents Of The University Of Texas System | A calculated index of genomic expression of estrogen receptor (er) and er related genes |
| EP2041307A2 (en) * | 2006-07-13 | 2009-04-01 | Siemens Healthcare Diagnostics GmbH | Prediction of breast cancer response to taxane-based chemotherapy |
| WO2008046182A1 (en) * | 2006-09-15 | 2008-04-24 | Mcgill University | Stroma derived predictor of breast cancer |
| AU2007329531B2 (en) | 2006-12-01 | 2013-10-10 | The Regents Of The University Of California | Vesicles of self-assembling block copolymers and methods for making and using the same |
| RU2473555C2 (ru) * | 2006-12-19 | 2013-01-27 | ДжинГоу, Инк. | Новые способы функционального анализа большого количества экспериментальных данных и групп генов, идентифицированных из указанных данных |
| ES2583377T3 (es) | 2007-06-08 | 2016-09-20 | Genentech, Inc. | Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2 |
| EP2036988A1 (en) | 2007-09-12 | 2009-03-18 | Siemens Healthcare Diagnostics GmbH | A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent |
| WO2009095319A1 (en) | 2008-01-28 | 2009-08-06 | Siemens Healthcare Diagnostics Gmbh | Cancer prognosis by majority voting |
| US8067178B2 (en) | 2008-03-14 | 2011-11-29 | Genomic Health, Inc. | Gene expression markers for prediction of patient response to chemotherapy |
| WO2009132928A2 (en) * | 2008-05-02 | 2009-11-05 | Siemens Healthcare Diagnostics Gmbh | Molecular markers for cancer prognosis |
| AU2009262894B2 (en) * | 2008-05-30 | 2014-01-30 | British Columbia Cancer Agency Branch | Gene expression profiles to predict breast cancer outcomes |
| RU2011101378A (ru) * | 2008-06-16 | 2012-07-27 | Сайвидон Дайагностикс Гмбх (De) | Алгоритмы предсказания исхода у пациентов с узловой формой рака молочной железы после химиотерапии |
| US20120053842A9 (en) | 2008-06-16 | 2012-03-01 | Sividon Diagnostics | Molecular markers for cancer prognosis |
| EP2163649A1 (en) * | 2008-09-11 | 2010-03-17 | Fédération Nationale des Centres de Lutte Contre le Cancer | Molecular classifier for evaluating the risk of metastasic relapse in breast cancer |
| KR101192297B1 (ko) | 2008-12-10 | 2012-10-17 | 한국생명공학연구원 | 간암에 대한 신규 바이오마커 및 그의 용도 |
| WO2010076322A1 (en) * | 2008-12-30 | 2010-07-08 | Siemens Healthcare Diagnostics Inc. | Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer |
| US20120065084A1 (en) | 2009-04-17 | 2012-03-15 | Universite Libre De Bruxelles | Methods and tools for predicting the efficiency of anthracyclines in cancer |
| JP2012527631A (ja) | 2009-05-22 | 2012-11-08 | ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンティド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシズ | タキサン型化学療法剤用のインジケータとしてのｓｅｒ４７３でのａｋｔリン酸化反応 |
| WO2011121028A1 (en) | 2010-03-30 | 2011-10-06 | Siemens Healthcare Diagnostics Inc. | Algorithm for prediction of benefit from addition of taxane to standard chemotherapy in patients with breast cancer |
| PL2553118T3 (pl) | 2010-03-31 | 2015-03-31 | Sividon Diagnostics Gmbh | Sposób przewidywania nawrotu raka sutka podczas leczenia endokrynologicznego |
| US20130042333A1 (en) | 2011-05-06 | 2013-02-14 | Jean-Gabriel JUDDE | Markers for cancer prognosis and therapy and methods of use |
| PL2737081T3 (pl) | 2011-07-28 | 2017-04-28 | Sividon Diagnostics Gmbh | Sposób przewidywania odpowiedzi na chemioterapię u pacjenta cierpiącego na lub u którego występuje ryzyko wystąpienia nawrotu raka sutka |
| AU2012344676A1 (en) | 2011-11-28 | 2014-06-19 | National Research Council Of Canada | Paclitaxel response markers for cancer |
| WO2013188600A1 (en) | 2012-06-12 | 2013-12-19 | Washington University | Copy number aberration driven endocrine response gene signature |
| WO2015121300A1 (en) | 2014-02-12 | 2015-08-20 | Sividon Diagnostics Gmbh | Method for predicting the response and survival from chemotherapy in patients with breast cancer |
| CN106480201A (zh) | 2016-10-26 | 2017-03-08 | 北京鑫诺美迪基因检测技术有限公司 | 乳腺癌转移评估试剂盒 |
-
2011
- 2011-03-29 PL PL11710526T patent/PL2553118T3/pl unknown
- 2011-03-29 JP JP2013501812A patent/JP5940517B2/ja active Active
- 2011-03-29 US US13/638,360 patent/US20130065786A1/en not_active Abandoned
- 2011-03-29 BR BR112012024718A patent/BR112012024718A2/pt not_active IP Right Cessation
- 2011-03-29 CN CN201610238134.6A patent/CN105821125A/zh active Pending
- 2011-03-29 PT PT117105262T patent/PT2553118E/pt unknown
- 2011-03-29 HU HUE14188791A patent/HUE030164T2/en unknown
- 2011-03-29 RU RU2012146343A patent/RU2654587C2/ru not_active IP Right Cessation
- 2011-03-29 WO PCT/EP2011/054855 patent/WO2011120984A1/en not_active Ceased
- 2011-03-29 MX MX2012011167A patent/MX2012011167A/es active IP Right Grant
- 2011-03-29 PT PT141887919T patent/PT2845911T/pt unknown
- 2011-03-29 CA CA2793133A patent/CA2793133C/en active Active
- 2011-03-29 PL PL14188791T patent/PL2845911T3/pl unknown
- 2011-03-29 UA UAA201212456A patent/UA110790C2/uk unknown
- 2011-03-29 BR BR122020016370-4A patent/BR122020016370B1/pt active IP Right Grant
- 2011-03-29 ES ES11710526.2T patent/ES2525382T3/es active Active
- 2011-03-29 EP EP14188791.9A patent/EP2845911B1/en not_active Not-in-force
- 2011-03-29 CN CN201180016811.5A patent/CN102971435B/zh active Active
- 2011-03-29 KR KR1020127025899A patent/KR101864855B1/ko active Active
- 2011-03-29 EP EP11710526.2A patent/EP2553118B1/en active Active
- 2011-03-29 ES ES14188791.9T patent/ES2587591T3/es active Active
-
2012
- 2012-09-27 ZA ZA2012/07229A patent/ZA201207229B/en unknown
-
2016
- 2016-05-18 JP JP2016099192A patent/JP2016189781A/ja not_active Abandoned
- 2016-08-11 US US15/234,828 patent/US10577661B2/en active Active
-
2020
- 2020-01-17 US US16/746,334 patent/US10851427B2/en active Active
- 2020-10-27 US US17/081,924 patent/US11913078B2/en active Active
-
2024
- 2024-01-11 US US18/410,966 patent/US20240229150A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201207229B (en) | Method for breast cancer recurrence prediction under endocrine treatment | |
| IL276362A (en) | Cancer treatment methods | |
| IL276488B (en) | A method for predicting breast cancer prognosis | |
| ZA201205003B (en) | Methods for treating breast cancer | |
| ZA201208815B (en) | Methods of treating bladder cancer | |
| PL2542585T3 (pl) | Sposoby leczenia nowotworu jelita grubego | |
| EP2643001A4 (en) | METHOD OF TREATING CANCER | |
| ZA201304225B (en) | Methods of treating cancer | |
| EP2771945A4 (en) | METHOD AND DEVICE FOR INTERCONNECTING ANTENNA HOOD AND PARABOLIC REFLECTOR | |
| IL254964A0 (en) | A method for treating breast cancer | |
| HRP20160851T1 (hr) | Prediktori za liječenje karcinoma | |
| HRP20181757T1 (hr) | Kombinirana terapija za liječenje raka dojke | |
| EP2640390A4 (en) | METHODS OF TREATING CANCER | |
| IL218230A0 (en) | Method of treating cancer | |
| PL2608802T3 (pl) | Immunoterapeutyczny sposób leczenia raka gruczołu krokowego | |
| EP2560648A4 (en) | METHOD OF TREATING PANCREATIC CANCER | |
| EP2560639A4 (en) | METHOD FOR THE TREATMENT OF PROSTATE CANCER | |
| EP2538944A4 (en) | METHOD FOR TREATING BRAIN TUMORS | |
| EP2707011A4 (en) | METHOD FOR THE TREATMENT OF PROSTATE CANCER | |
| GB201005367D0 (en) | Prediction of prostate cancer recurrence time | |
| ZA201208905B (en) | Cancer therapy method |